Literature DB >> 19966789

Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.

Darren M Hutt1, David Herman, Ana P C Rodrigues, Sabrina Noel, Joseph M Pilewski, Jeanne Matteson, Ben Hoch, Wendy Kellner, Jeffery W Kelly, Andre Schmidt, Philip J Thomas, Yoshihiro Matsumura, William R Skach, Martina Gentzsch, John R Riordan, Eric J Sorscher, Tsukasa Okiyoneda, John R Yates, Gergely L Lukacs, Raymond A Frizzell, Gerard Manning, Joel M Gottesfeld, William E Balch.   

Abstract

Chemical modulation of histone deacetylase (HDAC) activity by HDAC inhibitors (HDACi) is an increasingly important approach for modifying the etiology of human disease. Loss-of-function diseases arise as a consequence of protein misfolding and degradation, which lead to system failures. The DeltaF508 mutation in cystic fibrosis transmembrane conductance regulator (CFTR) results in the absence of the cell surface chloride channel and a loss of airway hydration, leading to the premature lung failure and reduced lifespan responsible for cystic fibrosis. We now show that the HDACi suberoylanilide hydroxamic acid (SAHA) restores surface channel activity in human primary airway epithelia to levels that are 28% of those of wild-type CFTR. Biological silencing of all known class I and II HDACs reveals that HDAC7 plays a central role in restoration of DeltaF508 function. We suggest that the tunable capacity of HDACs can be manipulated by chemical biology to counter the onset of cystic fibrosis and other human misfolding disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19966789      PMCID: PMC2901172          DOI: 10.1038/nchembio.275

Source DB:  PubMed          Journal:  Nat Chem Biol        ISSN: 1552-4450            Impact factor:   15.040


  50 in total

1.  Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis.

Authors:  Xiaodong Wang; John Venable; Paul LaPointe; Darren M Hutt; Atanas V Koulov; Judith Coppinger; Cemal Gurkan; Wendy Kellner; Jeanne Matteson; Helen Plutner; John R Riordan; Jeffery W Kelly; John R Yates; William E Balch
Journal:  Cell       Date:  2006-11-17       Impact factor: 41.582

Review 2.  Evidence for airway surface dehydration as the initiating event in CF airway disease.

Authors:  R C Boucher
Journal:  J Intern Med       Date:  2007-01       Impact factor: 8.989

Review 3.  New insights into cystic fibrosis: molecular switches that regulate CFTR.

Authors:  William B Guggino; Bruce A Stanton
Journal:  Nat Rev Mol Cell Biol       Date:  2006-06       Impact factor: 94.444

Review 4.  Histone deacetylase inhibitors: discovery and development as anticancer agents.

Authors:  Paul A Marks; Milos Dokmanovic
Journal:  Expert Opin Investig Drugs       Date:  2005-12       Impact factor: 6.206

5.  An acetylation site in the middle domain of Hsp90 regulates chaperone function.

Authors:  Bradley T Scroggins; Kenneth Robzyk; Dongxia Wang; Monica G Marcu; Shinji Tsutsumi; Kristin Beebe; Robert J Cotter; Sara Felts; David Toft; Larry Karnitz; Neal Rosen; Len Neckers
Journal:  Mol Cell       Date:  2007-01-12       Impact factor: 17.970

Review 6.  Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug.

Authors:  Paul A Marks; Ronald Breslow
Journal:  Nat Biotechnol       Date:  2007-01       Impact factor: 54.908

7.  Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents.

Authors:  H-S Lin; C-Y Hu; H-Y Chan; Y-Y Liew; H-P Huang; L Lepescheux; E Bastianelli; R Baron; G Rawadi; P Clément-Lacroix
Journal:  Br J Pharmacol       Date:  2007-02-26       Impact factor: 8.739

8.  Pharmacoproteomics of 4-phenylbutyrate-treated IB3-1 cystic fibrosis bronchial epithelial cells.

Authors:  Om V Singh; Neeraj Vij; Peter J Mogayzel; Cathy Jozwik; Harvey B Pollard; Pamela L Zeitlin
Journal:  J Proteome Res       Date:  2006-03       Impact factor: 4.466

9.  Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity.

Authors:  Emily A Bates; Martin Victor; Adriana K Jones; Yang Shi; Anne C Hart
Journal:  J Neurosci       Date:  2006-03-08       Impact factor: 6.167

Review 10.  The therapeutic uses of chromatin-modifying agents.

Authors:  Antonello Mai
Journal:  Expert Opin Ther Targets       Date:  2007-06       Impact factor: 6.902

View more
  138 in total

1.  Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease.

Authors:  Jie Lu; Chunzhang Yang; Masako Chen; Donald Y Ye; Russell R Lonser; Roscoe O Brady; Zhengping Zhuang
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

Review 2.  Hdac-mediated control of endochondral and intramembranous ossification.

Authors:  Elizabeth W Bradley; Meghan E McGee-Lawrence; Jennifer J Westendorf
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2011       Impact factor: 1.807

Review 3.  The delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiology.

Authors:  Christopher J Guerriero; Jeffrey L Brodsky
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

4.  Neurology of inherited glycosylation disorders.

Authors:  Hudson H Freeze; Erik A Eklund; Bobby G Ng; Marc C Patterson
Journal:  Lancet Neurol       Date:  2012-05       Impact factor: 44.182

5.  Correction of Niemann-Pick type C1 trafficking and activity with the histone deacetylase inhibitor valproic acid.

Authors:  Kanagaraj Subramanian; Darren M Hutt; Samantha M Scott; Vijay Gupta; Shu Mao; William E Balch
Journal:  J Biol Chem       Date:  2020-04-30       Impact factor: 5.157

6.  A posttranslational modification code for CFTR maturation is altered in cystic fibrosis.

Authors:  Sandra Pankow; Casimir Bamberger; John R Yates
Journal:  Sci Signal       Date:  2019-01-01       Impact factor: 8.192

7.  Quantitative Analysis of the Proteome Response to the Histone Deacetylase Inhibitor (HDACi) Vorinostat in Niemann-Pick Type C1 disease.

Authors:  Kanagaraj Subramanian; Navin Rauniyar; Mathieu Lavalleé-Adam; John R Yates; William E Balch
Journal:  Mol Cell Proteomics       Date:  2017-08-31       Impact factor: 5.911

8.  SAHA enhances Proteostasis of epilepsy-associated α1(A322D)β2γ2 GABA(A) receptors.

Authors:  Xiao-Jing Di; Dong-Yun Han; Ya-Juan Wang; Mark R Chance; Ting-Wei Mu
Journal:  Chem Biol       Date:  2013-11-07

9.  SYVN1, NEDD8, and FBXO2 Proteins Regulate ΔF508 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Ubiquitin-mediated Proteasomal Degradation.

Authors:  Shyam Ramachandran; Samantha R Osterhaus; Kalpaj R Parekh; Ashley M Jacobi; Mark A Behlke; Paul B McCray
Journal:  J Biol Chem       Date:  2016-10-18       Impact factor: 5.157

10.  Chemical corrector treatment ameliorates increased seizure susceptibility in a mouse model of familial epilepsy.

Authors:  Norihiko Yokoi; Yuko Fukata; Daisuke Kase; Taisuke Miyazaki; Martine Jaegle; Toshika Ohkawa; Naoki Takahashi; Hiroko Iwanari; Yasuhiro Mochizuki; Takao Hamakubo; Keiji Imoto; Dies Meijer; Masahiko Watanabe; Masaki Fukata
Journal:  Nat Med       Date:  2014-12-08       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.